Goldman Sachs Reports on Merck & Co (MRK)

In a report released yesterday by Goldman Sachs, the firm commented on Merck & Co. MRK. In the report, Goldman Sachs was mixed in its assessment. Goldman Sachs writes, “FDA granted MRK's Victrelis a limited label excluding null responders, which represents approximately 30% of treatment experienced patients. We see the exclusion of nulls as relatively in-line given the lack of prospective P3 trials and a 25% increase in cure rate vs. IFN/RBV. However, we believe the market expectations and our forecasts assuming a 25%/75% market split favoring TVR already reflect this.” Goldman Sachs currently has a Neutral rating on Merck & Co and a price target of $40. Shares of the company closed the trading day on Friday at $37.08, down $0.01 from the opening bell.